ASH 2022 | Post-authorization study of pomalidomide in R/R multiple myeloma with prior triple class exposure
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, outlines findings from a post-authorization study which evaluated the safety and survival outcomes of patients with relapsed/refractory (R/R) multiple myeloma treated with pomalidomide. Dr Ramasamy focused on data from a particular patient subgroup who had been treated with pomalidomide after being exposed to lenalidomide, bortezomib and dexamethasone (RVD). Overall, analysis found that patients with triple-class exposure had a shorter survival rate than double-refractory patients. Additionally, there were no safety concerns with pomalidomide in this subgroup. Due to the concerning survival rate, Dr Ramasamy believes better agents are needed for this particular subgroup of patients, such as BCMA-targeted therapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda, Bristol Myers Squibb, Janssen, Amgen, GlaxoSmithKline: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Travel, Research Funding, Speakers Bureau; Sanofi, Adaptive biotech, Oncopeptides: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau.
